The North America Isothermal Nucleic Acid Amplification Technology market is witnessing significant growth, driven by demand for rapid molecular diagnostics and technological innovations in point-of-care testing. The market size was valued at USD 590 Million in 2025 and is expected to reach USD 1,640 Million by 2035, growing at a CAGR of 9.7% from 2024 to 2035.
The economic impact of tariffs on "North America Isothermal Nucleic Acid Amplification Technology Market".
Market Growth Drivers
Increased Prevalence of Infectious Diseases: The rising incidence of infectious diseases such as COVID-19, influenza, and sexually transmitted infections has substantially fueled the demand for rapid and accurate molecular diagnostics in North America. Companies like Abbott and Hologic have expanded their isothermal nucleic acid amplification product portfolios to cater to diagnostic laboratories and point-of-care settings, ensuring quicker turnaround times compared to conventional PCR assays. Additionally, public health initiatives and favorable reimbursement policies are encouraging wider adoption of this technology in the healthcare sector.
Technological Advancements and Product Innovations: Major industry players, including Thermo Fisher Scientific and Bio-Rad Laboratories, are heavily investing in research and development to introduce advanced isothermal amplification platforms with higher sensitivity, specificity, and automation. These innovations facilitate robust detection in diverse sample matrices and promote the development of portable and user-friendly diagnostic devices. The integration of digital readout systems and connectivity features enhances data management, further supporting market expansion across clinical settings and decentralized testing environments.
Market Trends
Expansion of Point-of-Care Testing: The shift toward decentralized healthcare is propelling the adoption of isothermal nucleic acid amplification technologies at point-of-care sites. Companies such as Abbott (ID NOW platform) and Quidel Corporation have introduced compact, rapid molecular diagnostic devices suitable for clinics, pharmacies, and remote healthcare locations. The ongoing trend of miniaturized, easy-to-use tests is expected to dominate future product developments, offering laboratories and healthcare providers robust diagnostic capabilities outside traditional settings.
Collaboration and Strategic Partnerships: There is a notable increase in collaborations and strategic partnerships among diagnostic technology developers, hospitals, and research institutions to accelerate the adoption of advanced isothermal nucleic acid amplification tools. For instance, in 2024, Meridian Bioscience entered collaboration agreements with multiple hospitals to validate and deploy their Revogene molecular system, improving diagnostic accuracy and workflow efficiency. These partnerships drive market penetration and foster continuous innovation by leveraging shared expertise and resources.
Market Opportunities
Growing Demand for Home-based and Self-testing Solutions: As consumer awareness of health and wellness rises post-pandemic, several companies, including Lucira Health and Cue Health, are tapping into the opportunity to provide home-based isothermal amplification test kits for respiratory diseases and STDs. This market segment is expected to witness rapid growth due to convenience and accessibility.
Penetration in Veterinary and Agricultural Diagnostics: The utilization of isothermal nucleic acid amplification technologies for the detection of animal and plant diseases is gaining traction. Firms like BioMérieux are diversifying product lines to address biosecurity and food safety, targeting untapped sectors beyond human health diagnostics.
North America Isothermal Nucleic Acid Amplification Technology Market Revenue (USD Million), 2020-2035
The market revenue for North America's Isothermal Nucleic Acid Amplification Technology has shown a robust upward trajectory from 2020 to 2035. The market started at USD 230 million in 2020 and saw steady growth driven by the pandemic, increased R&D spending, and adoption in clinical diagnostics. By 2025, revenue reached USD 590 million, and it is projected to grow consistently, crossing USD 1,000 million by 2031 and reaching USD 1,640 million by 2035. This sustained growth is attributed to continuous product innovation, broader clinical applications, and the rise of decentralized testing models across North America.
Market Share by Region, 2025
In 2025, the United States dominates the North America Isothermal Nucleic Acid Amplification Technology Market, accounting for 69% of the total market share, primarily due to its advanced healthcare infrastructure, high adoption rates, and substantial R&D investments. Canada holds a 17% share, benefiting from increasing government funding towards molecular diagnostics. Mexico follows with an 8% share, driven by growing disease awareness and healthcare improvements. Remaining regions, including the Caribbean and Central America, contribute smaller shares due to developing healthcare systems and technological barriers. The regional distribution highlights the importance of the US market and emerging opportunities in Canada and Mexico.
Recent Developments
Abbott announced in February 2024 the launch of a next-generation ID NOW COVID-19 2.0 assay in the US, featuring improved sensitivity and faster results (under 10 minutes). This release responds to the ongoing need for rapid, reliable molecular diagnostics in decentralized healthcare settings, further expanding Abbott's reach in clinics and pharmacies.
In March 2024, Thermo Fisher Scientific unveiled a partnership with major US hospital networks to pilot its novel LAMP (Loop-mediated Isothermal Amplification) test panels across respiratory, gastrointestinal, and antimicrobial resistance diagnostics. The pilot aims to validate workflow integration and enhance point-of-care molecular assay availability.
April 2024 saw BioMérieux expand its commercial footprint in North America by launching isothermal nucleic acid amplification products designed specifically for veterinary clinics and agricultural monitoring. These solutions target rapid detection of zoonotic diseases and plant pathogens, diversifying applications and revenue streams outside traditional human health diagnostics.
Press Releases